Corporate Office: Mahendra Industrial Estate, Ground Floor, Plot No. 109-D, Road No. 29, Sion (East), Mumbai - 400 022. (India) Tel .: 022-2407 2249 / 2401 9025 (30 Lines) Fax.: 022-2407 3462 / 2407 0144

Email: admin@aartidrugs.com website: www.aartidrugs.com CIN No.:L37060MH1984PLC055433

Ref: ADL/SE/2022-23/4 April 16, 2022

To,
Listing/ Compliance Department **BSE Limited**Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400 001

To,
Listing/ Compliance Department
National Stock Exchange of India
Limited,

"Exchange Plaza", Plot No C/1, G Block, Bandra Kurla Complex, Bandra (E), Mumbai 400 051 NSE SYMBOL: AARTIDRUGS

BSE CODE - 524348

Dear Sir/Madam,

Sub: Compliance of Regulation 40(10) of SEBI (LODR) Regulations, 2015 for the half year ended March 31, 2022

We are forwarding herewith Certificate under Regulation 40(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 received from Jagdish Patel & Co., Practicing Company Secretary, for the half year ended March 31, 2022 for your perusal and record.

Kindly take the same on record.

Thanking you,

Yours faithfully,

FOR AARTI DRUGS LIMITED

RUSHIKESH DEOLE

COMPANY SECRETARY & COMPLIANCE OFFICER

ICSI M.No.: A54527



Rozy Empire, Silvassa Road,

Opp.: PWD Rest House, Vapi - 396 191,

Tele: 9324545141, Email:jppvapi13@csjpc.in 202, Prem Kutir CHS Ltd. Prem Nagar, Near MCF Udyan, Borivali (W)Mumbai 400092

Date - 15.04.2022

To,
The Board of Directors **Aarti Drugs Limited**,
Plot No. 198, M.I.D.C.,
Tarapur, Village - Pamtembhi,
Taluka & Dist. Palghar - 401 506.
Maharashtra.

Dear Sirs,

Sub: - Certificate under Regulation 40 (9) Of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

We have examined the data received on E-mail from Aarti Drugs Limited maintained by Link Intime India Private Limited (Registrar & Share Transfer Agent) pertaining to transfer of equity shares of the Company for the period from 1st April, 2021 to 31st March, 2022 for the purpose of issuing a Certificate as per Certificate under Regulation 40 (9) Of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 entered into by, Aarti Drugs Limited with BSE Limited and National Stock Exchange of India Limited based on the information provided by the Company and the Registrar & Share Transfer Agent, we hereby certify that the Company has issued for the year ended 31st March, 2022.

- A. Share Certificate(s) relating to the transfer of Shares, deletion of name, transmission of securities received during the period from 1st April, 2021 to 31st March, 2022 within the relaxed time lines provided by SEBI Circular No. SEBI/HO/MIRSD/DOP/CIR/P/2020/142 dated July 29, 2020 extended by SEBI circular no. SEBI/HO/MIRSD/RTAMB/CIR/P/2021/558 dated April 29, 2021 due to Covid-19 from the respective date of lodgment of each deed, as entered in the Memorandum of Transfers, excepting those rejected on technical grounds;
- B. The Share certificates received for duplicate/ consolidation during the year ended on 31st March, 2022, has been issued within thirty days of the lodgment, except those rejected on technical grounds.

FOR JAGDISH PATEL & CO.

Unique Code No.: P1991GJ052300

CS-2613

Company Secretaries,

Partner

CS Jagdish Patel

UDIN: F002613D000127971